Disc Medicine - About the company
Disc Medicine is a public company based in Cambridge (United States), founded in 2017 by Brian Mac Donald. It operates as a Developer of therapeutics for the treatment of hematologic diseases. Disc Medicine has raised $140M in funding from investors like Atlas Venture, Orbimed and Bain Capital Life Sciences. The company has 2520 active competitors, including 853 funded and 628 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Developer of therapeutics for the treatment of hematologic diseases. The company is developing therapeutic candidates based on fundamental pathways of red blood cell biology to treat hematologic diseases. The product pipeline includes Bitopertin for erythropoietic porphyrias, DISC-0974 for anemia of myelofibrosis, and matriptase-2 for myelodysplastic syndromes.
- Website
- www.discmedicine.com/
- Email ID
- *****@discmedicine.com
- Registered Address
- 321 ARSENAL ST STE 101,WATERTOWN,MA,02472,0
Key Metrics
Founded Year
2017
Location
Cambridge, United States
Stage
Public
Total Funding
$140M in 4 rounds
Latest Funding Round
Investors
Ranked
98th among 2520 active competitors
Employee Count
174 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Disc Medicine
Disc Medicine is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
DISC MEDICINE INC. CIN: 32089390200 , United States, Active | - | - | - | |
Disc Medicine, Inc. CIN: 1816736 , United States, Active | - | 23 (As on Dec 31, 2021) | - |
Disc Medicine's IPO details
Disc Medicine got listed on Dec 29, 2022.
Click here to take a look at Disc Medicine's IPO in detail
Sign up to download Disc Medicine's company profile
Disc Medicine's funding and investors
Disc Medicine has raised a total funding of $140M over 4 rounds. Its first funding round was on 2017. Its latest funding round was a Post IPO round on Feb 14, 2023 for $*****. 3 investors participated in its latest round. Disc Medicine has 14 institutional investors.
Here is the list of recent funding rounds of Disc Medicine:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 14, 2023 | 1260716 | Post IPO | 3380194 | 7065251 | 9473983 | 9185483 |
Sep 02, 2021 | 5798901 | Series B | 7639468 | 7992832 | 1610634 | |
Oct 29, 2019 | 3956514 | Series A | 8409056 | 7649862 |
Access funding benchmarks and valuations. Sign up today!View details of Disc Medicine's funding rounds and investors
Disc Medicine's founders and board of directors
Founder? Claim ProfileThe founders of Disc Medicine is Brian Mac Donald. Brian Mac Donald is the CEO of Disc Medicine.
Here are the details of Disc Medicine's key team members:
- Brian Mac Donald: Founder & CEO of Disc Medicine.
View details of Disc Medicine's Founder profiles and Board Members
Disc Medicine's employee count trend
Disc Medicine has 174 employees as of Sep 26. Here is Disc Medicine's employee count trend over the years:
Uncover Disc Medicine's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Disc Medicine's Competitors and alternates
Top competitors of Disc Medicine include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Disc Medicine, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
8th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
9th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
10th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
98th |  Disc Medicine 2017, Cambridge (United States), Public | Developer of therapeutics for the treatment of hematologic diseases | $140M | 64/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Disc Medicine's competitors? Click here to see the top ones
Disc Medicine's Investments and acquisitions
Disc Medicine has made no investments or acquisitions yet.
Reports related to Disc Medicine
Here is the latest report on Disc Medicine's sector:
News related to Disc Medicine
Filter this listMedia has covered Disc Medicine for a total of 44 events in the last 1 year, 18 of them have been about company updates and 1 about people movement.
•
•
Disc Medicine Presents Initial RESTORE-PV Phase 2 Trial Results in Polycythemia Vera PatientsGlobeNewswire•Sep 10, 2026•Disc Medicine
•
GoDaddy Inc. Securities Fraud Lawsuit Opportunity for InvestorsPR Newswire•Sep 10, 2026•Rosenlegal, GoDaddy, Kaplan Fox, Disc Medicine and 4 others
•
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact TheGlobeNewswire•Sep 02, 2026•Disc Medicine, Rosenlegal
•
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingGlobeNewswire•Sep 01, 2026•Disc Medicine
•
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationPR Newswire•Aug 18, 2026•Rosenlegal, Bloom Energy, Disc Medicine
•
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire•Jul 30, 2026•Disc Medicine
•
Rosen Law Firm Investigates Disc Medicine, Inc. Securities Class Action InvestigationPR Newswire•Jul 10, 2026•Disc Medicine, Rosenlegal
•
Disc Medicine COO Jonathan Yu sells $8,250 in stock By InvestingInvesting•Jul 09, 2026•Disc Medicine
•
4D Molecular Therapeutics Secures Strategic Credit Facility for up to $200 MillionGlobeNewswire•Jun 29, 2026•4D Molecular Therapeutics, Hercules Capital, Disc Medicine
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Disc Medicine
Explore our recently published companies
- NWNT Consulting Sarl, Genveva-Switzerland - Switzerland based, 2016 founded, Unfunded company
- Creative Ops - United Kingdom based, Unfunded company
- Print3DPro - Unfunded company
- AIZA - Palo Alto based, 2023 founded, Series A company
- Sunandsuncattlefeed - Raipur based, 2017 founded, Unfunded company
- KG Latvija - Sigulda based, 2014 founded, Unfunded company
